开发α-Synuclein Fibril乱区域的抑制剂,以缓解帕金森病的病理
Shenqing Zhang1,2, Huaijiang Xiang3,4, Youqi Tao1,2
1Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China.
Journal of the American Chemical Society
|September 27, 2024
概括
研究人员发现一种化合物可以阻止α-syn纤维在帕金森病 (PD) 中扩散. 这种小分子向C端内在乱区域 (IDR),减少神经元损伤和炎症.
科学领域:
- 神经科学
- 生物化学
- 药理学
背景情况:
- 阿尔法-同核素 (α-syn) 的粉状纤维是帕金森病 (PD) 病理学的核心.
- α-syn纤维素的C端内在乱区域 (IDR) 与LAG3和RAGE等受体相互作用,促进神经元的扩散和炎症.
研究的目的:
- 识别破坏α-syn纤维素与神经元受体相互作用的抑制剂.
- 开发针对α-syn IDR的新型小分子,用于治疗PD.
主要方法:
- 高通量查以确定Givinostat (GS) 是一个α-syn纤维素抑制剂.
- 优化GS的结构-活性关系研究,导致化合物GSD-16-24.
- 溶液状态和固态NMR,以及冷电子显微镜 (cryo-EM) 来阐明结合机制.
主要成果:
- GSD-16-24被确定为一种强有力的抑制剂,结合单体和纤维形式的α-syn C-终端IDR.
- GSD-16-24有效地阻止α- syn纤维素与LAG3和RAGE受体结合.
- 该化合物显著降低了α-syn纤维介导的神经元扩散和促炎反应.
结论:
- 通过像GSD-16-24这样的小分子准α-syn C-终端IDR为帕金森病提供了一种新的治疗策略.
- 破坏α-syn纤维素受体相互作用可以缓解PD中的关键病理过程.
- 这种方法为开发治疗帕金森病的新临床药物提供了潜在的线索.
相关概念视频
01:15Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495
01:24Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K